Posted by Michael Wonder on 15 Jul 2021
G-BA sees “considerable additional benefit” in two active ingredients - EU HTA analysis is coming
15 July 2021 - The Federal Joint Committee (G-BA) today certified two active ingredients with a "considerable additional benefit". It assigns the second-best category based on the extent of the additional benefit that is available to it.
The G-BA also saw a clue of an additional benefit for two active ingredients against certain forms of cancer.
Following the latest agreement on an EU regulation on health technology assessment, cancer drugs will probably be the first drugs for which the G-BA will include a joint clinical assessment in the future.
